IRON Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Disc Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$63.40 |
| 52 Week High | US$77.60 |
| 52 Week Low | US$25.60 |
| Beta | 0 |
| 1 Month Change | -2.01% |
| 3 Month Change | 26.98% |
| 1 Year Change | 3.95% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 218.75% |
Recent News & Updates
Disc Medicine, Inc. (NASDAQ:IRON) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 02
Disc Medicine: Achieving Functional Endpoint More Important
Oct 06Recent updates
Disc Medicine, Inc. (NASDAQ:IRON) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 02Disc Medicine: Achieving Functional Endpoint More Important
Oct 06Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans
Aug 13Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress
Jun 14Disc Medicine: What's Behind The Huge Rally
Jan 31Shareholder Returns
| IRON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.3% | -2.3% | -2.6% |
| 1Y | 4.0% | -6.3% | 24.5% |
Return vs Industry: IRON exceeded the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: IRON underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| IRON volatility | |
|---|---|
| IRON Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IRON has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IRON's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 82 | John Quisel | www.discmedicine.com |
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders.
Disc Medicine, Inc. Fundamentals Summary
| IRON fundamental statistics | |
|---|---|
| Market cap | US$1.89b |
| Earnings (TTM) | -US$103.48m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-18.2x
P/E RatioIs IRON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRON income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$103.48m |
| Earnings | -US$103.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.48 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IRON perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 19:15 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Disc Medicine, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Douglas Tsao | H.C. Wainwright & Co. |